EA201001688A1 - Производные арилпиразинона стимуляторы секреции инсулина, способы их получения и их применение для лечения диабета - Google Patents

Производные арилпиразинона стимуляторы секреции инсулина, способы их получения и их применение для лечения диабета

Info

Publication number
EA201001688A1
EA201001688A1 EA201001688A EA201001688A EA201001688A1 EA 201001688 A1 EA201001688 A1 EA 201001688A1 EA 201001688 A EA201001688 A EA 201001688A EA 201001688 A EA201001688 A EA 201001688A EA 201001688 A1 EA201001688 A1 EA 201001688A1
Authority
EA
Eurasian Patent Office
Prior art keywords
derivatives
diabetes
treatment
insulin secretion
arylpyrazinine
Prior art date
Application number
EA201001688A
Other languages
English (en)
Other versions
EA022345B1 (ru
Inventor
Жерар Боттон
Эрик Валё
Кристине Шарон
Мишлине Кергоат
Самер Эльбаваб
Original Assignee
Мерк Патент Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мерк Патент Гмбх filed Critical Мерк Патент Гмбх
Publication of EA201001688A1 publication Critical patent/EA201001688A1/ru
Publication of EA022345B1 publication Critical patent/EA022345B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
    • C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/18—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Настоящее изобретение относится к производным арилпиразинона формулы (I), где R1, R2, R3 и А имеют значения, указанные в п.1, в качестве стимуляторов секреции инсулина. Изобретение также относится к получению и применению этих производных пиразинона для профилактики и/или лечения диабета и связанных патологий.
EA201001688A 2008-04-29 2009-03-31 Производные арилпиразинона в качестве стимуляторов секреции инсулина, способы их получения и их применение для лечения диабета EA022345B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08008165 2008-04-29
PCT/EP2009/002328 WO2009132739A1 (en) 2008-04-29 2009-03-31 Arylpyrazinone derivatives insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes

Publications (2)

Publication Number Publication Date
EA201001688A1 true EA201001688A1 (ru) 2011-06-30
EA022345B1 EA022345B1 (ru) 2015-12-30

Family

ID=40589704

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201001688A EA022345B1 (ru) 2008-04-29 2009-03-31 Производные арилпиразинона в качестве стимуляторов секреции инсулина, способы их получения и их применение для лечения диабета

Country Status (25)

Country Link
US (2) US8815859B2 (ru)
EP (1) EP2268624B1 (ru)
JP (1) JP5498482B2 (ru)
KR (1) KR101687419B1 (ru)
CN (1) CN102015661B (ru)
AR (1) AR071518A1 (ru)
AU (1) AU2009242720B2 (ru)
BR (1) BRPI0910833A2 (ru)
CA (1) CA2722813C (ru)
CO (1) CO6310997A2 (ru)
CY (1) CY1114531T1 (ru)
DK (1) DK2268624T3 (ru)
EA (1) EA022345B1 (ru)
EC (1) ECSP10010642A (ru)
ES (1) ES2433210T3 (ru)
HR (1) HRP20130992T1 (ru)
IL (1) IL208959A (ru)
MX (1) MX2010011792A (ru)
NZ (1) NZ589555A (ru)
PL (1) PL2268624T3 (ru)
PT (1) PT2268624E (ru)
SI (1) SI2268624T1 (ru)
UA (1) UA103191C2 (ru)
WO (1) WO2009132739A1 (ru)
ZA (1) ZA201008505B (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2736472A1 (en) * 2008-09-26 2010-04-01 F. Hoffmann-La Roche Ag Pyrine or pyrazine derivatives for treating hcv
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013066838A1 (en) * 2011-10-31 2013-05-10 Glaxosmithkline Llc Compounds and methods
CN104628661A (zh) * 2015-02-05 2015-05-20 北京理工大学 一类喹喔啉酮衍生物作为醛糖还原酶抑制剂的结构、制备方法及用途
CN114907323B (zh) * 2022-05-31 2023-08-15 内蒙古民族大学 喹喔啉酮类化合物及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62198671A (ja) * 1986-02-25 1987-09-02 Toyo Jozo Co Ltd １−置換アルキル１，２−ジヒドロ−２−ピラジノン誘導体
RU2003135424A (ru) * 2001-05-14 2005-05-20 Бристол-Маерс Сквибб Фарма Компани (Us) Замещенные пиразиноны, пиридины и пиримидины в качестве лигандов кортикотропин высвобождающего фактора
PT1534391E (pt) * 2002-07-19 2007-05-31 Biovitrum Ab Novos derivados e piperazinilo-pirazinona para o tratamento de desordens relacionadas com o receptor 5-ht
FR2857867B1 (fr) * 2003-07-25 2005-10-14 Oreal Utilisation en coloration capillaire de derives de ninhydrine portant un groupe heteroalkyle
WO2005097136A1 (en) 2004-03-29 2005-10-20 Merck & Co., Inc. Biaryl substituted pyrazinones as sodium channel blockers
WO2006050506A1 (en) * 2004-11-03 2006-05-11 Curis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto
TW200640881A (en) * 2005-02-15 2006-12-01 Du Pont Fungicidal pyrazine derivatives
CN101341135B (zh) 2005-12-21 2013-08-14 詹森药业有限公司 治疗mch-1介导的疾病的取代的吡嗪酮衍生物
CN101505747A (zh) * 2006-06-21 2009-08-12 杜邦公司 作为细胞增殖抑制剂的吡嗪酮

Also Published As

Publication number Publication date
EP2268624A1 (en) 2011-01-05
CO6310997A2 (es) 2011-08-22
AU2009242720B2 (en) 2014-03-27
NZ589555A (en) 2012-08-31
CY1114531T1 (el) 2016-10-05
EP2268624B1 (en) 2013-07-31
PT2268624E (pt) 2013-11-07
CA2722813A1 (en) 2009-11-05
US20110046159A1 (en) 2011-02-24
CA2722813C (en) 2017-03-21
KR20100135313A (ko) 2010-12-24
US8815859B2 (en) 2014-08-26
ES2433210T3 (es) 2013-12-09
EA022345B1 (ru) 2015-12-30
BRPI0910833A2 (pt) 2015-08-11
HRP20130992T1 (hr) 2013-11-22
IL208959A0 (en) 2011-01-31
MX2010011792A (es) 2010-11-25
SI2268624T1 (sl) 2013-12-31
US20140329837A1 (en) 2014-11-06
ECSP10010642A (es) 2010-12-30
CN102015661B (zh) 2014-05-14
ZA201008505B (en) 2012-01-25
US9233937B2 (en) 2016-01-12
JP2011518847A (ja) 2011-06-30
IL208959A (en) 2015-09-24
AR071518A1 (es) 2010-06-23
KR101687419B1 (ko) 2016-12-19
PL2268624T3 (pl) 2014-01-31
CN102015661A (zh) 2011-04-13
JP5498482B2 (ja) 2014-05-21
UA103191C2 (ru) 2013-09-25
AU2009242720A1 (en) 2009-11-05
WO2009132739A1 (en) 2009-11-05
DK2268624T3 (da) 2013-11-04

Similar Documents

Publication Publication Date Title
EA201001407A1 (ru) Производные хиноксалинона в качестве стимуляторов секреции инсулина, способы их получения и их применение для лечения диабета
EA201201030A1 (ru) 5-алкинилпиримидины
NZ598085A (en) Methods, compounds, and compositions for delivering 1,3-propanedisulfonic acid
EA201001408A1 (ru) Производные пиразинона как стимуляторы секреции инсулина, способы их получения и их применение для лечения диабетов
EA201190217A1 (ru) Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение
EA201071045A1 (ru) Соединения оксадиазоантрацена для лечения диабета
EA201070422A1 (ru) Производные оксадиазола
EA201200318A1 (ru) Гетероциклические оксимы
EA201071264A1 (ru) Аминодигидротиазиновые производные в качестве ингибиторов bace для лечения болезни альцгеймера
EA201200918A1 (ru) Производные пирролидин карбоновой кислоты как агонисты сопряженного с g-белком рецептора 43 (gpr43), фармацевтическая композиция и методы их использования при лечении метаболических нарушений
TN2012000249A1 (en) Pyrazine derivatives and their use in the treatment of neurological disorders
MY149648A (en) Carboxylalkylene-phenyl)-phenyl-oxalamides, method for the production thereof, and use of same as a medicament
EA201200176A1 (ru) Производные оксазина и их применение для лечения неврологических нарушений
CL2011002604A1 (es) Compuestos derivados de n-(cianometil)-4-(sulfonil)pirrolidina-2-carboxamida, inhibidores de catepsina s o l; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento o profilaxis de la diabetes, aterosclerosis, aneurismo aortico abdominal, enfermedades arteriales periferica o la nefropatia diabetica.
EA201200174A1 (ru) Производные оксазина и их применение в качестве ингибиторов bace для лечения неврологических нарушений
NO20083514L (no) Heterobicykliske sulfonamidderivater for behandling av diabetes
EA201100255A1 (ru) 5-алкинилпиримидины
MX2010002419A (es) (ciclopropilfenil) feniloxamidas, metodo para su produccion y uso como un medicamento.
CY1111733T1 (el) Παραγωγα 2-(1η-ινδολυλοσουλφανυλ)-βενζυλαμινης ως ssri
EA200802214A1 (ru) 2,4-диаминопиримидины в качестве ингибиторов киназ, участвующих в регуляции клеточного цикла
EA201171211A1 (ru) Производные оксадиазола
EA201001405A1 (ru) Стимуляторы секреции инсулина - производные пиридопиразинонов, способы их получения и их применение для лечения диабета
EA201100254A1 (ru) Новые соединения
JO2682B1 (en) Derivatives of alkynil-8.1-naphthayridone, preparations thereof and therapeutic use thereof
EA201170983A1 (ru) Производные тиадиазолов и оксадиазолов, их получение и их применение в терапии

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU